Inogen, Inc. (INGN) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions.
Analysis Summary
Inogen, Inc. reported revenue of $348.7M in the most recent fiscal year, growing at a 5-year CAGR of 2.5%.
Trailing-twelve-month margins: gross margin 48.9%, operating margin -8.4%, net margin -6.9%.
At the current price of $5.13, INGN has negative trailing earnings (P/E not meaningful) and an ROE of -13.17%. Market capitalisation stands at $139M.
Balance sheet quality for INGN: current ratio of 3.1, net cash position of $102.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $5.13 |
| Market Cap | $139M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.81 |
| EV / EBITDA | -10.46 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -13.17% |
| Return on Invested Capital | -13.35% |
| Return on Assets | -8.61% |
| Gross Margin | 48.89% |
| Operating Margin | -8.45% |
| Net Margin | -6.94% |
Financial Health
| Debt / Equity | 0.09 |
| Current Ratio | 2.74 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 1.58 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| INGN | Inogen, Inc. | $139M | 0.81 | -13.2% | |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 28.37 | 4.41 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $65.3B | 17.84 | 2.62 | 14.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price Performance
| 1 month | -8.39% |
| 3 months | -19.97% |
| Year-to-date | -23.66% |
| 1 year | -38.34% |
| 3 years | -5.00% |
| 5 years | -89.58% |
52-Week Range
| 52-week High | $9.13 |
| 52-week Low | $5.10 |
| Avg Volume (90d) | 292K |
Related companies: CATX · EPRX · HCAT · HSDT · NNOX · OM · QTRX
Explore sector: Healthcare · Medical - Devices
More sections of INGN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks